On Jun 26, we issued an updated research report on Amedisys, Inc. AMED. The stock carries a Zacks Rank #2 (Buy). Shares of this renowned home health and hospice services provider have outperformed the broader industry over the past three months. The stock has surged 40.3% against the 18.4% decline of the industry. At the Home Health and Hospice divisions, Amedisys is witnessing encouraging growth in Medicare and non-Medicare revenues. The company is currently exploring opportunities in these segments. In this regard, Amedisys recently acquired the hospice care provider RoseRock Healthcare. This apart, with the acquisition of Compassionate Care Hospice, Amedisys now has ADC (average daily census) of 9,982, making it the third largest Hospice organization in the country. We are also impressed by the company’s solid performance in the recently-launched Personal Care segment. A favorable demographic trend and strategic buyouts bode well too. Of late, the company integrated a new operating segment into its Personal Care business. During the reported quarter, net service revenues totaled $20 million with total hours per quarter growing approximately 11%. Per management, this segment ...